Recoil Therapeutics
Restoring the body's mechanical architecture to reverse tissue aging — starting with skin
Why It Matters
Aging and tissue decline is the result of fiber breakdown in the extra-cellular matrix (ECM). Loss of fibers accelerates with aging leading to tissue dysfunction.
90% of 2025 U.S. healthcare expenditure ($4.4T) spent on aging-related chronic diseases
Tissue degradation over time contributes to mechanical breakdown, followed by biological malfunction
Treatments focus on symptoms but not the underlying root cause
What We Do
Recoil Therapeutics is an early-stage biomaterials company developing an injectable platform that restores extracellular matrix mechanics. We engineer novel chemistry to replace ECM fibers.
Indications
Skin
LeadCollagen and elastic fibers breakdown in skin
Joint Cartilage
Type II collagen fibers deteriorate
Intervertebral Discs
Degeneration of Type I Collagen Fibers
Our Approach
Engineered biomaterial scaffolds — injectable, non-biological, and designed to recreate the physical microenvironment required for tissue function and health.
Why This Wins
Clear Biological Target
Elastin loss is a primary driver of tissue aging
Mechanism-Driven Approach
Rebuilding structure, not temporary filling
Expandable Platform
Skin today, multiple tissues tomorrow
De-Risked Path to Market
Lead Indication: Skin
Faster regulatory pathway
Localized Delivery
Reduced systemic risk
Biomaterial Approach
Precedent in clinical use
Investment
Pre-Seed Round
Founders
Team
Faizan Zubair
Co-Founder & CEO
Chemical & Biomolecular Engineering PhD 10 years in pharma & startups
Joseph Kuo
Co-Founder & COO
Immunology PhD · MBA Business development in life sciences
Paul Laibinis
Scientific Advisor
Chair, Chemical Engineering at Vanderbilt Trained at Whitesides Lab
Aubrey de Grey
Scientific Advisor
President & CSO at LEV Foundation ECM Biology & Longevity